MRI of gastric carcinoma： Results of T and N-staging in an in vitro study

AIM： To determine the accuracy of 1.5-T magnetic resonance imaging （MRI） in the evaluation of gastric wall invasion and perigastric lymph node metastasis in gastric adenocarcinoma.
METHODS： Twenty resected gastric specimens containing 20 tumors were studied with a 1.5-T MR system using a commercial head surface coil. MR scanning was performed with a T1 weighted image （TR/TE = 500/20）, and a T2 weighted image （TR/TE = 2500/90）. MR findings were compared with pathologic findings.
RESULTS： A T1-weighted image demonstrated three layers in the normal gastric wall. All of the gastric tumors were well demonstrated by lesions and location. In a MRI findings of gastric wall invasion, there was 1 case of T1, 7 of T2, 11 of T3. Pathologic results of resected specimens included 3 cases of pT1, 4 of pT2, and 12 of pT3. The accuracy of T staging with MRI was 74% （14 of 19）. MRI findings of lymph node metastasis included 6 cases of NO, 13 cases of N1. The accuracy of the N staging with MRI was 47% （9 of 19）.
CONCLUSION： MRI has a high diagnostic accuracy in the evaluation of the T staging of gastric cancerin vitro and thus potentially enables preoperative histopathologic staging.     

Effectiveness and safety of splenectomy for gastric carcinoma： A meta-analysis

AIM: To evaluate the impact of splenectomy on long-term survival, postoperative morbidity and mortality of patients with gastric cancer by performing a meta-analysis.METHODS: A search of electronic databases to identify randomized controlled trials in The Cochrane Library trials register, Medline, CBMdisc (Chinese Biomedical Database) and J-STAGE, etc was performed. Data was extracted from the studies by 2 independent reviewers. Outcome measures were survival, postoperative morbidity and mortality and operation-related events. The meta-analyses were performed by RevMan 4.3.RESULTS: Three studies comprising 466 patients were available for analysis, with 231 patients treated by gastrectomy plus splenectomy. Splenectomy could not increase the 5-year overall survival rate [RR = 1.17, 95% confidence interval (CI) 0.97-1.41]. The postoperative morbidity (RR = 1.76, 95% CI 0.82-3.80) or mortality (RR = 1.58, 95% CI 0.45-5.50) did not suggest any significant differences between the 2 groups. No significant differences were noted in terms of number of harvested lymph nodes, operation time, length of hospital stay and reoperation rate. Subgroup analyses showed splenectomy did not increase the survival rate for proximal and whole gastric cancer. No obvious differences were observed between the 2 groups when stratified by stage. Sensitivity analyses indicated no significant differences regarding the survival rates (P > 0.05).CONCLUSION: Splenectomy did not show a beneficial effect on survival rates compared to splenic preservation. Routinely performing splenectomy should not be recommended.     

Adenoviral gene therapy in gastric cancer： A review

Gastric cancer is one of the most common malignancies worldwide. With current therapeutic approaches the prognosis of gastric cancer is very poor, as gastric cancer accounts for the second most common cause of death in cancer related deaths. Gastric cancer like almost all other cancers has a molecular genetic basis which relies on disruption in normal cellular regulatory mechanisms regarding cell growth, apoptosis and cell division. Thus novel therapeutic approaches such as gene therapy promise to become the alternative choice of treatment in gastric cancer. In gene therapy, suicide genes, tumor suppressor genes and anti-angiogenesis genes among many others are introduced to cancer cells via vectors. Some of the vectors widely used in gene therapy are Adenoviral vectors. This review provides an update of the new developments in adenoviral cancer gene therapy including strategies for inducing apoptosis, inhibiting metastasis and targeting the cancer cells.     

Prognostic factors in patients with node-negative gastric carcinoma： A comparison with node-positive gastric carcinoma

AIM: To identify the clinicopathological characteristics of lymph node-negative gastric carcinoma, and also to evaluate outcome indicators in the lymph node-negative patients. METHODS: Of 2848 gastric carcinoma patients, 1524 (53.5%) were lymph node-negative. A statistical analysis was performed using the Cox model to estimate outcome indicators. RESULTS: There was a significant difference in the recurrence rate between lymph node-negative and lymph node-positive patients (14.4% vs 41.0%, P<0.001). The 5-year survival rate was significantly lower in lymph node-positive than in lymph node-negative patients (31.1% vs 77.4%, P<0.001). Univariate analysis revealed that the following factors influenced the 5-year survival rate: patient age, tumor size, depth of invasion, tumor location, operative type, and tumor stage at initial diagnosis. The Cox proportional hazard regression model revealed that tumor size, serosal invasion, and curability were independent, statistically significant, prognostic indicators of lymph node-negative gastric carcinoma. CONCLUSION: Lymph node-negative patients have a favorable outcome attributable to high curability, but the patients with relatively large tumors and serosal invasion have a poor prognosis. Curability is one of the most reliable predictors of long-term survival for lymph node-negative gastric carcinoma patients.     

Effect of pseudolaric acid B on gastric cancer cells： Inhibition of proliferation and induction of apoptosis

AIM: To examine the effect of pseudolaric acid B on the growth of human gastric cancer cell line, AGS, and its possible mechanism of action. METHODS: Growth inhibition by pseudolaric acid B was analyzed using MTT assay. Apoptotic cells were detected using Hoechst 33258 staining, and confirmed by DNA fragmentation analysis. Western blot was used to detect the expression of apoptosis-regulated gene Bcl-2, caspase 3, and cleavage of poly (ADP-ribose) polymerase-1 (PARP-1). RESULTS: Pseudolaric acid B inhibited the growth of AGS cells in a time- and dose-dependent manner by arresting the cells at G2/M phase, which was accompanied with a decrease in the levels of cdc2. AGS cells treated with pseudolaric acid B showed typical characteristics of apoptosis including chromatin condensation and DNA fragmentation. Moreover, treatment of AGS cells with pseudolaric acid B was also associated with decreased levels of the anti-apoptotic protein Bcl-2, activation of caspase-3, and proteolytic cleavage of PARP-1. CONCLUSION: Pseudolaric acid B can dramatically suppress the AGS cell growth by inducing apoptosis after G2/M phase arrest. These findings are consistent with the possibility that G2/M phase arrest is mediated by the down-regulation of cdc2 levels. The data also suggest that pseudolaric acid B can trigger apoptosis by decreasing Bcl-2 levels and activating caspase-3 protease.     

Distribution of solitary lymph nodes in primary gastric cancer： A retrospective study and clinical implications

AIM To investigate the distribution pathway of metastatic lymph nodes in gastric carcinoma as a foundation for rational lymphadenectomy.METHODS We investigated 173 cases with solitary or single station metastatic lymph nodes (LN) from among 2476 gastric carcinoma patients. The location of metastatic LN, histological type and growth patterns were analyzed retrospectively.RESULTS Of 88 solitary node metastases cases, 65 were limited to perigastric nodes (N1), while 23 showed skipping metastasis. Among 8 tumors in the upper third stomach, 3 involved right paracardial LN (station number No.1), and one in the greater curvature was found in No.1. In the 28 middle third stomach tumors, 10were found in LN of the lesser curvature (No.3) and 6 in LN of the left gastric artery (No.7); 5 of the 20 cases on the lesser curvature spread to No.7, while 2 of the 8 on the greater curvature metastasized to LN of the spleen hilum (No.10). Of 52 lower third stomach tumors, 13 involved in No.3 and 19 were detected in inferior pyloric LN (No.6); 9 of the 29 cases along the lesser curvature were involved in No.6.CONCLUSION Transversal and skipping metastases of sentinel lymph nodes (SLN) are notable, and rational lymphadenectomy should, therefore, be performed.     

Spiral CT in gastric carcinoma： Comparison with barium study, fiberoptic gastroscopy and histopathology

AIM: To evaluate spiral computed tomography (CT) including virtual gastroscopy for diagnosis of gastric carcinoma in comparison with upper gastrointestinal series (UGI), fiberoptic gastroscopy (FG) and histopathology. METHODS: Sixty patients with histologically proven gastric carcinoma (54 advanced and 6 early) were included in this study. The results of spiral CT were compared with those of UGI and FG. Two observers blindly evaluated images of spiral CT and UGI and video recording of FG with consensus in terms of diagnostic confidence with a five-point scale. Sensitivities of lesion detection, Borrmann‘‘s classification of spiral CT, UGI and FG, as well as the accuracy of TNM staging of spiral CT were determined by comparing them to surgical and histological findings. RESULTS: The lesion detection rate was 98 % (5g/60), 95 % (57/60) and 98 % (59/60) for spiral CT, UGI and FG, respectively. There were no statistical differences in the detection sensitivity among the three techniques (P&gt;0.05).For the sensitivity in Borrmann‘‘s classification, spiral CT was higher than that of UGI (P=0.025) and similar to that of FG (P&gt;0.05). The accuracy of spiral CT in staging the gastric carcinoma was 76.7 %. Six cases of early gastric carcinoma were all detected by spiral CT as well as FG. CONCLUSION: Spiral CT is equivalent to UGI and FG in the detection of gastric carcinoma, and superior to UGI but similar to FG in the Borrmann‘‘s classification of advanced gastric carcinoma. Spiral CT is more valuable than FG in the staging of gastric carcinoma.     

Clinicopathologic characteristics of gastric carcinoma in elderly patients： A comparison with young patients

AIM: To examine the clinicopathologic features of elderly patients with gastric carcinoma and to investigate the relationship between prognosis and age. METHODS: We reviewed the hospital records of 2 014 patients with gastric carcinoma retrospectively to compare the clinicopathologic findings in elderly (age＞70 years) and young (age＜36 years) patients during the period from 1986 to 2000 in a tertiary referral center in Gwangju, Korea. Overall survival was the main outcome measure. RESULTS: Of the 2 014 patients, 194 (9.6%) were in the elderly group and 137 (6.8%) were in the young group. The elderly and young patients had similar distributions with respect to depth of invasion, nodal involvement, hepatic metastasis, peritoneal dissemination, tumor stage at the initial diagnosis, and type of surgery. Synchronous multiple carcinomas were found in 14/194 (7.2%) of the elderly group and 4/137 (2.9%) of the young group (P＜0.05). Using the Borrmann classification, type Ⅳ was more frequent in the young patients than in the elderly patients (P＜0.05). Significantly more elderly patients had a well or moderately differentiated histology, and more young patients had a poorly differentiated histology and signet ring cell carcinoma (P＜0.001). The 5-year survival rates of elderly and young patients did not differ statistically (52.8% vs 46.5%, P=0.5290). Multivariate analysis showed that the histologic type, nodal involvement and operative curability were significant prognostic factors, and age itself was not an independent prognostic factor of survival for elderly gastric carcinoma patients. CONCLUSION: Elderly patients with gastric carcinoma do not have a worse prognosis than young patients. The important prognostic factor is whether the patients undergo a curative resection.     

Expression of E-selectin, integrin β1 and immunoglobulin superfamily member in human gastric carcinoma cells and its clinicopathologic significance

AIM: To study the expression levels of E- selectin, integrin beta1 and immunoglobulin superfamily member-intercellular adhesion molecule-1 (ICAM-1) in human gastric carcinoma cells, and to explore the relationship between these three kinds of cell adhesion molecules and gastric carcinoma. METHODS: The serum contents of E-selectin, integrin beta1 and ICAM-1 were detected by enzyme-linked immunosorbent assay (ELISA), in 47 healthy individuals (control group) and in 57 patients with gastric carcinoma (gastric carcinoma group) respectively prior to operation and 7 d after operation.RESULTS: The serum E-selectin, ECAM-1 and integrin beta1 were found to be expressed in both control and gastric carcinoma groups. However, they were highly expressed in patients with gastric carcinoma patients before operation or with unresectable tumours. The expression levels of ICAM-1 and integrin beta1 were significantly higher in gastric carcinoma patients than in controls (P < 0.01). A comparison of the E-selectin levels between the two groups showed statistically insignificant difference (P = 0.64). In addition, the expression levels were all decreased substantially in the postoperative patients subjected to radical resection of the tumours, indicating that the high level expressions of these compounds might be the important factor for predicting the prognosis of these patients. CONCLUSION: Serum E-selectin, ICAM-1 and integrin beta1 expression levels are probably related to the metastasis and relapse of gastric cancer.     

Clinical and experimental study of oxaliplatin in treating human gastric carcinoma

AIM:To evaluate the therapeutic effectiveness of oxaliplatinon human gastric carcinoma and to explore its mechanisms.METHODS:Twenty-two cases of stage IV gastric carcinomareceived 4-6(mean 4.6)cycles of first line combinedchemotherapy with oxaliplatin(oxaliplatin 85 mg/m~2,iv,gtt,1 h,d 1;leukovorin 200 mg/m~2,iv,gtt,1 h,d 1 and d 2;5-FU 300 mg/m~2,iv,d 1 and d 2,5-FU,continuous iv,gtt,48 h;1 cycle/2 wk).Response rate,progression-free survival(PFS),total survival time,toxic side effects were evaluated.The inhibitory effect of oxaliplatin on human gastric cell lineSGC-7901 was detected and IC_(50) was calculated by MTT.Transmission electron microscopy,flow cytometry andTUNEL were performed to evaluate the apoptosis of cellline induced by the drug.The expression of Caspase-3m-RNA was detected by RT-PCR.AC-DEVD-CHO,aCaspase-3 specific inhibitor,was used to elucidate the roleof activated Caspase-3 in the process of apoptosis inducedby oxaliplatin.RESULTS:Total response(complete and partial)occurredin 9(40.9%) patients.Mean PFS was 4.2 mo and meantotal survival time was 7.2 mo.Cumulative neurotoxicity(all grade Ⅰ-Ⅱ),vomiting and diarrhea,myelosuppressionappeared in 93.5%,20%,32.9% patients,respectively.IC_(50) was calculated to be 0.71 mg/L by MTT assay.A maximalinhibitory rate reached 85.3%.Apoptosis index was elevatedafter incubated with 1 mmol/L oxaliplatin for 30 min,butwithout statistic significance(P>0.05).However it couldbe detected at a much higher degree both by flowcytometryand by TUNEL with a statistical significance(68.47±7.92%and 8.23±2.67%,respectively,P<0.05)after incubated with1 mmol/L oxaliplatin for 2 d.By means of RT-PCR,we detectedan enhancement of Caspase-3 m-RNA expression inducedby oxaliplatin which was also in positive correlation withthe apoptotic level.AC-DEVD-CHO,a Caspase-3 specificinhibitor,could significantly inhibit and delay apoptosisinduced by oxaliplatin.CONCLUSION:Oxaliplatin is effective and well-toleratedin patients with advanced gastric carcinoma.Oxaliplatincould significantly inhibit the growth of human gastric cell lineSGC-7901.The induction of Caspase-3 m-RNA expression,activation of Caspase-3 and promotion of apoptosis maybe some of the therapeutic mechanisms of oxaliplatin ongastric carcinoma.Annexin-V-fluorescein labeling flowcytometry is much more sensitive than TUNEL in detecting early stage apoptosis.     

用基因表达谱芯片研究人正常胃和胃癌中与发育相关基因的价值

用8464条人cDNA制成表达谱芯片,利用胃和胃癌组织的mRNA,通过逆转录方法将Cy3和Cy5两种荧光分别标记到两组cDNA上,利用这种cDNA探针与表达谱芯片进行杂交后扫描,通过计算机分析判定基因是否在上述组织中存在差异表达,结果示在197条与生长发育相关的基因中,存在差异表达的共10条,上调的8条（0．095％）,下调的2条（0．024％）,应用这种方法识别出的基因对胃癌的诊断和治疗具有重要的潜在价值。     

基因芯片技术在胃黏膜病变中的研究进展

胃癌及癌前病变的发生涉及环境、表观遗传学和多种遗传基因的异常,基因芯片技术在分析基因表达谱和甲基化等方面取得了一定进展.此文对基因芯片技术在胃黏膜病变研究中的应用做一介绍,并探讨和其他技术相结合的新进展.     

基因芯片在肺癌发生相关基因筛查中的应用

目的 研究人肺癌发生相关基因表达谱,探讨肺癌发生的分子机制。方法 选取1280个与肿瘤相关的基因克隆。制备成肿瘤相关cDNA芯片。提取人肺癌组织以及相应正常组织RNA,反转录后标记为cDNA探针,与cDNA芯片杂交,经扫描及Quantarray3．0软件分析后比较两种组织中的差异表达基因。结果 共筛查出差异表达基因52条。其中表达上调基因35条,下调基因17条;按照基因功能可分为运输载体,代谢相关基因、细胞信号转导分子、细胞骨架、转录调控因子以及未知功能基因。结论 基因芯片可用于肺癌相关基因表达谱的筛查,为明确肺癌发生机制提供重要参考。     

Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance

AIM: To investigate the expression of three types of mucin(MUC1, MUC2, MUC5AC) and E-cadherin in human gastric carcinomas and their clinical significance. METHODS: Ninety-four gastric cancer specimens were classified according to WHO criteria and detected by immunohistochemical assay of expression of mucins and E-cadherin. RESULTS: The positive expression rates of MUC1, MUC2, MUC5AC and E-cadherin were 82% (77/94), 84% (79/94), 40% (38/94) and 56% (53/94) respectively. MUC1 expression was significantly correlated with the types of cancer (the positive rates of MUC1 in well and moderately differentiated tubular adenocardnoma, poorly differentiated adenocardnoma, signet-ring cell carcinoma and mucinous carcinoma were 91%, 87%, 71%, 71%, respectively, P&lt;0.05), age of patients (the positive rates of it among the people who are younger than 40 years, between 40-60 years and over 60 yearwere 74%, 81%, 89%, P&lt;0.05), lymph nodes involvement (the positive rates in the non-interfered group and the interfered group were 78%, 85%, P&lt;0.05) and tumor size (the positive rates in the tumors with the size less than 3 cm, 3-6 cm and larger than 6 cm were 69%, 92%, 69%, P&lt;0.05); MUC2 expression was significantly associated with types of cancers and had the strongest expression in mucinous carcinomas (the posrdve rates of MUC2 in well and moderately differentiated tubular adenocardnoma, poorly differentiated adenocardnoma,signet-ring cell carcinoma and mucinous carcinoma were 94%, 70%, 81%, 100%, P&lt;0.05), but it had no obvious relation to age, gender, tumor location, lymph nodes involvement,depth of invasion and metastasis to extra-gastric organs (P&gt;0.05); MUC5AC expression was not related to any of the characteristics investigated except that it had relation to gender, whereas MUC5AC showed the tendency to higher expression in less invasive lesions and lower expression in advanced stage cancers (P&gt;0.05); No significant difference was found for E-cadherin expression. There were strong positive relationships between the expression of MUC1 and E-cadherin, MUC2 and E-cadherin, MUC1 and MUC2(R=0.33, R=0.22, R=0.32, respectively, P&lt;0.05). According to the COX proportional hazards model, older patients, involvement of lymph nodes, different types of gastri ccancer and MUC2 expression were significantly associated with poorer outcome of gastric carcinoma patients (β=0.08,β=3.94, β=1.33, β=0.75, respectively, P&lt;0.05). CONCLUSION: MUC1 and MUC2 are good markers of different types of gastric cancer. MUC2 is especially a good marker of mucinous carcinoma. MUCl, MUC2 may interfere with the function of E-cadherin in gastric carcinomas, and have synergic effect on progression of gastric cancers.     

Differential gene and protein expression in primary gastric carcinomas and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis

OBJECTIVE: To gain insight into the molecular events of lymph node metastasis of human gastric carcinoma. METHODS: The gene expression profile of five matched primary gastric carcinomas and their lymph node metastases was analyzed by complementary DNA (cDNA) microarray. Differential genes were identified in the metastatic and corresponding primary tumor pairs. Among the differentially expressed genes, carbonic anhydrase II (CAII) and insulin-like growth factor binding protein 4 (IGFBP 4) genes were detected by RT-PCR. CTTN protein expression was examined by tissue microarray. RESULTS: There was a high expression (over twofold) of 44 genes and a low expression (under twofold) of 32 genes in lymph node metastasis compared with primary gastric carcinoma, respectively. CAII mRNA was downregulated and IGFBP 4 mRNA was upregulated in paired lymph node metastases of gastric carcinomas. The overexpression of CTTN protein was related to the lymph node metastasis and the clinical stage of gastric carcinomas. CONCLUSION: This study showed that there is a low expression of genes relative to growth signal and immune response in lymph node metastases, and a high expression of genes relative to growth factor, cell cycle, cell motility and adhesion in lymph node metastases compared with primary gastric carcinomas. The expression of CTTN was related to the invasion and metastasis of gastric cancer.     

利用组织芯片技术研究PTEN和VEGF在胃癌中的表达及意义

目的研究PTEN和血管内皮生长因子（vascular endothelial growth factor，VEGF）在胃癌中的表达及临床意义。方法应用组织微阵列仪制作97孔胃癌组织芯片（tissue microarray）。用免疫组织化学S—P法检测PTEN、VEGF在72例胃癌和25例正常胃黏膜中的表达。结果胃癌组织中PTEN蛋白阳性表达率显著低于正常胃黏膜（45．8％ VS 100％，P〈0．01）；VEGF的阳性表达率显著高于正常胃黏膜（75％VSl2％，P〈0．01），PTEN在胃癌中的表达与VEGF呈负相关（P〈0．01）。PTEN、VEGF的表达在中高分化腺癌分别为68．8％、62．5％（P〉0．05），在低分化及未分化腺癌分别为27．5％、85．0％（P〈0．05）；伴淋巴结转移者分别为31．6％、86．9％（P〈0．05），无淋巴结转移者分别为61．8％、61。8％（P〉0．05）；临床病理分期Ⅰ＋Ⅱ期分别为57．1％、61．9％（P〉0．05），Ⅲ＋Ⅳ期分别为30．0％、93．3％（P〈0．05）；与性别、年龄、肿瘤大小和组织分型无显著差异（P〉0．05）。结论PTEN失活或蛋白表达降低、VEGF的高表达与胃癌临床病理特征和生物学行为有密切关系。PTEN在低分化或未分化以及伴淋巴结转移和临床Ⅲ＋Ⅳ期胃癌中的表达与VEGF呈负相关。联合检测PTEN、VEGF对胃癌的恶性程度及预后判断具有一定的临床参考意义。应用组织芯片大规模高效检测临床组织样本是可行的，具有快速、准确、方便经济的特点。     

MMP-7与Fas蛋白在胃癌组织中的表达及意义

目的:探讨基质金属蛋白酶-7(MMP-7)蛋白和Fas蛋白在胃癌组织中的表达、相互关系及意义.方法:应用免疫组化方法检测了82例胃癌组织及30例周边正常胃黏膜中MMP-7和Fas的表达情况.结果:胃癌组织中MMP-7蛋白阳性率显著高于正常胃黏膜(73.2%vs10%,P<0.001);正常胃黏膜中Fas蛋白阳性率显著高于胃癌组织(39.1%vs93.3%,P<0.001).MMP-7阳性表达率与淋巴结转移、TNM分期显著相关(P<0.001),而与肿瘤细胞分化程度无显著性相关.Fas蛋白阳性表达率与肿瘤细胞分化程度显著相关(P<0.05),而与淋巴结转移、TNM分期无显著性相关.胃癌组织中MMP-7与Fas表达具有显著等级负相关(r=-0.597,P<0.001).结论:MMP-7与Fas表达胃癌的生物学行为密切相关,且两者之间的表达强度具有显著等级负相关.     

P27和Fas在胃癌组织中的表达及其临床意义

目的研究P27和Fas在不同病理类型胃癌组织中的表达,以探讨P27和Fas在胃癌发生中的作用与其预后的关系。方法应用免疫组化SP法检测P27、Fas在135例胃癌组织及45例正常胃黏膜组织中的表达情况,胃癌病理组织学分型应用HE染色法。结果胃癌组织中P27、Fas阳性表达率分别为45.93%和42.96%,明显低于正常胃黏膜组织的84.44%和77.78%,胃高中分化腺癌P27阳性表达率(65.45%)高于胃低分化腺癌(33.96%)和黏液癌(40.74%)(P均<0.05),胃高中分化腺癌Fas阳性表达率(60.00%)也明显高于胃低分化腺癌(33.96%)和黏液癌(33.33%)(P均<0.05),P27和Fas阳性表达在胃低分化腺癌与胃黏液癌之间均无显著性差异;无淋巴结转移组P27和Fas阳性表达率分别为48.00%和72.00%,均明显高于有淋巴结转移组的22.50%和40.00%;术后生存期≥5年的胃癌组织中P27表达阳性率(52.63%),Fas表达阳性率(57.89%)均高于生存期<5年组两者阳性表达率(均为16.67%),胃癌组织中P27阳性者的Fas阳性表达率显著高于P27阴性者(P<0.05),二者呈正相关。结论胃癌组织中P27、Fas表达下降,二者在胃癌中的低表达可能与胃癌的分型、恶性程度、淋巴结转移及生存期有关,对胃癌的发生可能起协同作用。检测胃癌组织中P27和Fas的表达有助于判断肿瘤的进展程度和预后。     

胃癌组织芯片中Argonaute蛋白表达分析

目的 检测胃癌Argonautel、Argonaute2、Argonaute3和Argonaute4蛋白表达,探讨其临床意义.方法 利用组织芯片技术结合免疫组化法检测100例胃癌组织和癌旁组织中Argonaute1、Argonaute2、Argonaute3和Argonaute4蛋白的表达.结果 胃癌组织中Argonautel、Argonaute2,Argonaute3和Argonaute4蛋白表达均显著高于癌旁组织(P＜0.05);Ⅱ～Ⅱ期胃癌中4种蛋白表达均显著高于癌旁组织(P＜0.05);Argonaute4蛋白在Ⅲ期胃癌中的表达显著高于Ⅰ～Ⅱ期胃癌(P＜0.05),Argonaute1、Argonaute2、Argonaute3蛋白在在Ⅰ～Ⅱ期胃癌与Ⅲ期胃癌间差异无统计学意义(P＞0.05).四种Argonaute蛋白的表达与胃癌患者的性别、年龄、淋巴结转移无相关性(P＞0.05).在胃癌组织中Argonautel、Argonaute2、Argonaute3和Argonaute4蛋白两两间表达存在相关性(P＜0.01).结论 胃癌的发生发展可能与Argonaute1、Argonaute2、Argonaute3和Argonaute4蛋白过表达有关.